ImmunityBio FY2026 Earnings Forecast Lifted by HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of ImmunityBio in a research note issued on Thursday, October 15th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.26) per share for the year, up from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.44) per share.

Several other research firms have also recently weighed in on IBRX. Piper Sandler restated an “overweight” rating and set a $16.00 target price on shares of ImmunityBio in a research note on Wednesday, October 14th. Jefferies Financial Group increased their price target on shares of ImmunityBio from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, October 6th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX opened at $8.77 on Wednesday. ImmunityBio has a fifty-two week low of $1.95 and a fifty-two week high of $12.43. The firm has a market capitalization of $9.29 billion, a PE ratio of -9.04 and a beta of 0.02. The stock’s 50-day simple moving average is $8.61 and its 200-day simple moving average is $7.99.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.70 million.

Insiders Place Their Bets

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $10.50, for a total transaction of $851,088.00. Following the transaction, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This trade represents a 44.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the transaction, the director directly owned 2,777,788 shares in the company, valued at approximately $29,861,221. The trade was a 0.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by insiders.

Institutional Trading of ImmunityBio

Institutional investors and hedge funds have recently made changes to their positions in the company. Markowski Investments acquired a new stake in shares of ImmunityBio in the 2nd quarter valued at about $29,000. GAMMA Investing LLC increased its position in ImmunityBio by 262.2% during the third quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock worth $36,000 after buying an additional 2,756 shares during the period. Geneos Wealth Management Inc. increased its position in ImmunityBio by 579.3% during the first quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after buying an additional 4,907 shares during the period. Western Wealth Management LLC acquired a new stake in shares of ImmunityBio in the first quarter valued at approximately $44,000. Finally, Hollencrest Capital Management purchased a new position in shares of ImmunityBio during the second quarter worth approximately $44,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.